nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—UGT1A1—urine—polycystic ovary syndrome	0.00644	0.0177	CbGeAlD
Nilotinib—MAPK8—embryo—polycystic ovary syndrome	0.00418	0.0115	CbGeAlD
Nilotinib—CDC42BPB—adrenal cortex—polycystic ovary syndrome	0.00379	0.0104	CbGeAlD
Nilotinib—EPHB3—embryo—polycystic ovary syndrome	0.00345	0.00948	CbGeAlD
Nilotinib—Contusion—Metformin—polycystic ovary syndrome	0.00337	0.0309	CcSEcCtD
Nilotinib—Chest discomfort—Metformin—polycystic ovary syndrome	0.00333	0.0305	CcSEcCtD
Nilotinib—BLK—adrenal gland—polycystic ovary syndrome	0.00313	0.00861	CbGeAlD
Nilotinib—CDC42BPB—uterus—polycystic ovary syndrome	0.00312	0.00857	CbGeAlD
Nilotinib—MAPK11—adipose tissue—polycystic ovary syndrome	0.00307	0.00846	CbGeAlD
Nilotinib—CDC42BPB—pituitary gland—polycystic ovary syndrome	0.00306	0.00842	CbGeAlD
Nilotinib—CDC42BPB—adipose tissue—polycystic ovary syndrome	0.00305	0.00839	CbGeAlD
Nilotinib—TIE1—adrenal cortex—polycystic ovary syndrome	0.00297	0.00817	CbGeAlD
Nilotinib—EPHA3—adipose tissue—polycystic ovary syndrome	0.00289	0.00795	CbGeAlD
Nilotinib—EPHA4—embryo—polycystic ovary syndrome	0.00288	0.00792	CbGeAlD
Nilotinib—MAPK8—uterus—polycystic ovary syndrome	0.00282	0.00775	CbGeAlD
Nilotinib—FRK—endocrine gland—polycystic ovary syndrome	0.00281	0.00774	CbGeAlD
Nilotinib—MAPK8—pituitary gland—polycystic ovary syndrome	0.00277	0.00762	CbGeAlD
Nilotinib—MAPK11—adrenal gland—polycystic ovary syndrome	0.00276	0.00758	CbGeAlD
Nilotinib—MAPK8—adipose tissue—polycystic ovary syndrome	0.00276	0.00758	CbGeAlD
Nilotinib—CDC42BPB—adrenal gland—polycystic ovary syndrome	0.00273	0.00752	CbGeAlD
Nilotinib—CYP2C9—urine—polycystic ovary syndrome	0.00271	0.00745	CbGeAlD
Nilotinib—MAPK14—embryo—polycystic ovary syndrome	0.00265	0.0073	CbGeAlD
Nilotinib—FGR—embryo—polycystic ovary syndrome	0.00264	0.00727	CbGeAlD
Nilotinib—HCK—adrenal cortex—polycystic ovary syndrome	0.0026	0.00714	CbGeAlD
Nilotinib—EPHA3—adrenal gland—polycystic ovary syndrome	0.00259	0.00713	CbGeAlD
Nilotinib—MAPK11—female gonad—polycystic ovary syndrome	0.00257	0.00707	CbGeAlD
Nilotinib—CDC42BPB—female gonad—polycystic ovary syndrome	0.00255	0.00701	CbGeAlD
Nilotinib—BRAF—endometrium—polycystic ovary syndrome	0.00254	0.007	CbGeAlD
Nilotinib—CDC42BPB—vagina—polycystic ovary syndrome	0.00253	0.00697	CbGeAlD
Nilotinib—EPHB3—endometrium—polycystic ovary syndrome	0.00252	0.00694	CbGeAlD
Nilotinib—Ear pain—Metformin—polycystic ovary syndrome	0.0025	0.023	CcSEcCtD
Nilotinib—MAP4K1—adipose tissue—polycystic ovary syndrome	0.0025	0.00689	CbGeAlD
Nilotinib—MAPK8—adrenal gland—polycystic ovary syndrome	0.00247	0.0068	CbGeAlD
Nilotinib—TIE1—uterus—polycystic ovary syndrome	0.00244	0.00672	CbGeAlD
Nilotinib—TEK—embryo—polycystic ovary syndrome	0.00241	0.00663	CbGeAlD
Nilotinib—TIE1—adipose tissue—polycystic ovary syndrome	0.00239	0.00658	CbGeAlD
Nilotinib—CDC42BPB—endocrine gland—polycystic ovary syndrome	0.00237	0.00652	CbGeAlD
Nilotinib—BRAF—uterus—polycystic ovary syndrome	0.00234	0.00645	CbGeAlD
Nilotinib—EPHB3—uterus—polycystic ovary syndrome	0.00232	0.0064	CbGeAlD
Nilotinib—HCK—endometrium—polycystic ovary syndrome	0.00232	0.00638	CbGeAlD
Nilotinib—MAPK8—female gonad—polycystic ovary syndrome	0.0023	0.00634	CbGeAlD
Nilotinib—BRAF—pituitary gland—polycystic ovary syndrome	0.0023	0.00633	CbGeAlD
Nilotinib—MAPK8—vagina—polycystic ovary syndrome	0.00229	0.0063	CbGeAlD
Nilotinib—BRAF—adipose tissue—polycystic ovary syndrome	0.00229	0.0063	CbGeAlD
Nilotinib—MAP4K1—adrenal gland—polycystic ovary syndrome	0.00225	0.00618	CbGeAlD
Nilotinib—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.00219	0.0201	CcSEcCtD
Nilotinib—PDGFRA—embryo—polycystic ovary syndrome	0.00218	0.006	CbGeAlD
Nilotinib—Lethargy—Metformin—polycystic ovary syndrome	0.00218	0.02	CcSEcCtD
Nilotinib—EPHA6—endocrine gland—polycystic ovary syndrome	0.00214	0.0059	CbGeAlD
Nilotinib—MAPK8—endocrine gland—polycystic ovary syndrome	0.00214	0.0059	CbGeAlD
Nilotinib—TIE1—adrenal gland—polycystic ovary syndrome	0.00214	0.0059	CbGeAlD
Nilotinib—Pain in extremity—Metformin—polycystic ovary syndrome	0.00214	0.0196	CcSEcCtD
Nilotinib—HCK—uterus—polycystic ovary syndrome	0.00214	0.00588	CbGeAlD
Nilotinib—Migraine—Metformin—polycystic ovary syndrome	0.0021	0.0193	CcSEcCtD
Nilotinib—HCK—pituitary gland—polycystic ovary syndrome	0.0021	0.00577	CbGeAlD
Nilotinib—HCK—adipose tissue—polycystic ovary syndrome	0.00209	0.00575	CbGeAlD
Nilotinib—ABL2—pituitary gland—polycystic ovary syndrome	0.00208	0.00574	CbGeAlD
Nilotinib—MAP4K1—vagina—polycystic ovary syndrome	0.00208	0.00573	CbGeAlD
Nilotinib—ABL2—adipose tissue—polycystic ovary syndrome	0.00208	0.00571	CbGeAlD
Nilotinib—CYP3A4—urine—polycystic ovary syndrome	0.00206	0.00568	CbGeAlD
Nilotinib—EPHB4—adrenal cortex—polycystic ovary syndrome	0.00206	0.00567	CbGeAlD
Nilotinib—BRAF—adrenal gland—polycystic ovary syndrome	0.00205	0.00566	CbGeAlD
Nilotinib—EPHB3—adrenal gland—polycystic ovary syndrome	0.00204	0.00561	CbGeAlD
Nilotinib—CYP2D6—urine—polycystic ovary syndrome	0.00203	0.00559	CbGeAlD
Nilotinib—EPHA2—adrenal cortex—polycystic ovary syndrome	0.00202	0.00557	CbGeAlD
Nilotinib—TIE1—female gonad—polycystic ovary syndrome	0.002	0.0055	CbGeAlD
Nilotinib—Dehydration—Metformin—polycystic ovary syndrome	0.00199	0.0182	CcSEcCtD
Nilotinib—LYN—endocrine gland—polycystic ovary syndrome	0.00198	0.00544	CbGeAlD
Nilotinib—TEK—adrenal cortex—polycystic ovary syndrome	0.00197	0.00543	CbGeAlD
Nilotinib—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.00195	0.0179	CcSEcCtD
Nilotinib—EPHA4—uterus—polycystic ovary syndrome	0.00194	0.00534	CbGeAlD
Nilotinib—FGR—endometrium—polycystic ovary syndrome	0.00193	0.00532	CbGeAlD
Nilotinib—Breast disorder—Metformin—polycystic ovary syndrome	0.00193	0.0177	CcSEcCtD
Nilotinib—CSF1R—embryo—polycystic ovary syndrome	0.00192	0.00529	CbGeAlD
Nilotinib—CA3—uterus—polycystic ovary syndrome	0.00192	0.00528	CbGeAlD
Nilotinib—BRAF—female gonad—polycystic ovary syndrome	0.00192	0.00527	CbGeAlD
Nilotinib—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.00191	0.0175	CcSEcCtD
Nilotinib—EPHA4—pituitary gland—polycystic ovary syndrome	0.00191	0.00525	CbGeAlD
Nilotinib—BRAF—vagina—polycystic ovary syndrome	0.0019	0.00524	CbGeAlD
Nilotinib—EPHB3—female gonad—polycystic ovary syndrome	0.0019	0.00523	CbGeAlD
Nilotinib—EPHA4—adipose tissue—polycystic ovary syndrome	0.0019	0.00522	CbGeAlD
Nilotinib—EPHB3—vagina—polycystic ovary syndrome	0.00189	0.0052	CbGeAlD
Nilotinib—CA3—pituitary gland—polycystic ovary syndrome	0.00188	0.00518	CbGeAlD
Nilotinib—CA3—adipose tissue—polycystic ovary syndrome	0.00187	0.00516	CbGeAlD
Nilotinib—HCK—adrenal gland—polycystic ovary syndrome	0.00187	0.00516	CbGeAlD
Nilotinib—ABL2—adrenal gland—polycystic ovary syndrome	0.00186	0.00512	CbGeAlD
Nilotinib—Abdominal distension—Metformin—polycystic ovary syndrome	0.00186	0.017	CcSEcCtD
Nilotinib—Influenza—Metformin—polycystic ovary syndrome	0.00185	0.0169	CcSEcCtD
Nilotinib—EPHB4—endometrium—polycystic ovary syndrome	0.00184	0.00507	CbGeAlD
Nilotinib—Pancreatitis—Metformin—polycystic ovary syndrome	0.00181	0.0166	CcSEcCtD
Nilotinib—EPHA2—endometrium—polycystic ovary syndrome	0.00181	0.00497	CbGeAlD
Nilotinib—Angina pectoris—Metformin—polycystic ovary syndrome	0.0018	0.0165	CcSEcCtD
Nilotinib—MAPK14—uterus—polycystic ovary syndrome	0.00179	0.00492	CbGeAlD
Nilotinib—LCK—uterus—polycystic ovary syndrome	0.00178	0.0049	CbGeAlD
Nilotinib—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.00177	0.0162	CcSEcCtD
Nilotinib—TEK—endometrium—polycystic ovary syndrome	0.00176	0.00485	CbGeAlD
Nilotinib—MAPK14—pituitary gland—polycystic ovary syndrome	0.00176	0.00484	CbGeAlD
Nilotinib—FGR—pituitary gland—polycystic ovary syndrome	0.00175	0.00482	CbGeAlD
Nilotinib—MAPK14—adipose tissue—polycystic ovary syndrome	0.00175	0.00482	CbGeAlD
Nilotinib—HCK—female gonad—polycystic ovary syndrome	0.00175	0.00481	CbGeAlD
Nilotinib—KIT—embryo—polycystic ovary syndrome	0.00174	0.0048	CbGeAlD
Nilotinib—LCK—adipose tissue—polycystic ovary syndrome	0.00174	0.0048	CbGeAlD
Nilotinib—FGR—adipose tissue—polycystic ovary syndrome	0.00174	0.0048	CbGeAlD
Nilotinib—HCK—vagina—polycystic ovary syndrome	0.00174	0.00478	CbGeAlD
Nilotinib—ABL2—female gonad—polycystic ovary syndrome	0.00174	0.00478	CbGeAlD
Nilotinib—Neutropenia—Metformin—polycystic ovary syndrome	0.00173	0.0158	CcSEcCtD
Nilotinib—ABL2—vagina—polycystic ovary syndrome	0.00173	0.00475	CbGeAlD
Nilotinib—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.00172	0.0157	CcSEcCtD
Nilotinib—PDGFRB—embryo—polycystic ovary syndrome	0.0017	0.00469	CbGeAlD
Nilotinib—EPHA4—adrenal gland—polycystic ovary syndrome	0.0017	0.00469	CbGeAlD
Nilotinib—EPHB4—uterus—polycystic ovary syndrome	0.0017	0.00467	CbGeAlD
Nilotinib—EPHB6—endometrium—polycystic ovary syndrome	0.00168	0.00463	CbGeAlD
Nilotinib—EPHB4—pituitary gland—polycystic ovary syndrome	0.00167	0.00458	CbGeAlD
Nilotinib—EPHB4—adipose tissue—polycystic ovary syndrome	0.00166	0.00457	CbGeAlD
Nilotinib—Infestation—Metformin—polycystic ovary syndrome	0.00165	0.0151	CcSEcCtD
Nilotinib—Infestation NOS—Metformin—polycystic ovary syndrome	0.00165	0.0151	CcSEcCtD
Nilotinib—EPHA2—pituitary gland—polycystic ovary syndrome	0.00163	0.0045	CbGeAlD
Nilotinib—EPHA2—adipose tissue—polycystic ovary syndrome	0.00163	0.00448	CbGeAlD
Nilotinib—HCK—endocrine gland—polycystic ovary syndrome	0.00162	0.00447	CbGeAlD
Nilotinib—TEK—uterus—polycystic ovary syndrome	0.00162	0.00447	CbGeAlD
Nilotinib—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.00161	0.0148	CcSEcCtD
Nilotinib—MAP2K5—adrenal cortex—polycystic ovary syndrome	0.00161	0.00444	CbGeAlD
Nilotinib—TEK—pituitary gland—polycystic ovary syndrome	0.00159	0.00439	CbGeAlD
Nilotinib—TEK—adipose tissue—polycystic ovary syndrome	0.00159	0.00437	CbGeAlD
Nilotinib—EPHA4—female gonad—polycystic ovary syndrome	0.00159	0.00437	CbGeAlD
Nilotinib—EPHA4—vagina—polycystic ovary syndrome	0.00158	0.00434	CbGeAlD
Nilotinib—CSF1R—adrenal cortex—polycystic ovary syndrome	0.00157	0.00433	CbGeAlD
Nilotinib—MAPK14—adrenal gland—polycystic ovary syndrome	0.00157	0.00432	CbGeAlD
Nilotinib—LCK—adrenal gland—polycystic ovary syndrome	0.00156	0.0043	CbGeAlD
Nilotinib—FGR—adrenal gland—polycystic ovary syndrome	0.00156	0.0043	CbGeAlD
Nilotinib—CA3—vagina—polycystic ovary syndrome	0.00156	0.00429	CbGeAlD
Nilotinib—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.00156	0.0143	CcSEcCtD
Nilotinib—CA14—adrenal gland—polycystic ovary syndrome	0.00153	0.0042	CbGeAlD
Nilotinib—EPHB6—pituitary gland—polycystic ovary syndrome	0.00152	0.00419	CbGeAlD
Nilotinib—ABL1—embryo—polycystic ovary syndrome	0.00152	0.00418	CbGeAlD
Nilotinib—EPHB6—adipose tissue—polycystic ovary syndrome	0.00152	0.00418	CbGeAlD
Nilotinib—Bradycardia—Metformin—polycystic ovary syndrome	0.00151	0.0138	CcSEcCtD
Nilotinib—EPHB4—adrenal gland—polycystic ovary syndrome	0.00149	0.0041	CbGeAlD
Nilotinib—Rhinitis—Metformin—polycystic ovary syndrome	0.00148	0.0136	CcSEcCtD
Nilotinib—Hepatitis—Metformin—polycystic ovary syndrome	0.00148	0.0136	CcSEcCtD
Nilotinib—EPHA4—endocrine gland—polycystic ovary syndrome	0.00148	0.00406	CbGeAlD
Nilotinib—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.00147	0.0135	CcSEcCtD
Nilotinib—PDGFRA—uterus—polycystic ovary syndrome	0.00147	0.00405	CbGeAlD
Nilotinib—MAPK14—female gonad—polycystic ovary syndrome	0.00146	0.00403	CbGeAlD
Nilotinib—EPHA2—adrenal gland—polycystic ovary syndrome	0.00146	0.00402	CbGeAlD
Nilotinib—CA3—endocrine gland—polycystic ovary syndrome	0.00146	0.00401	CbGeAlD
Nilotinib—FGR—female gonad—polycystic ovary syndrome	0.00146	0.00401	CbGeAlD
Nilotinib—LCK—female gonad—polycystic ovary syndrome	0.00146	0.00401	CbGeAlD
Nilotinib—Oedema peripheral—Metformin—polycystic ovary syndrome	0.00146	0.0134	CcSEcCtD
Nilotinib—MAPK14—vagina—polycystic ovary syndrome	0.00145	0.004	CbGeAlD
Nilotinib—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.00145	0.0133	CcSEcCtD
Nilotinib—LCK—vagina—polycystic ovary syndrome	0.00145	0.00399	CbGeAlD
Nilotinib—FGR—vagina—polycystic ovary syndrome	0.00145	0.00399	CbGeAlD
Nilotinib—MAP2K5—endometrium—polycystic ovary syndrome	0.00144	0.00396	CbGeAlD
Nilotinib—PDGFRA—adipose tissue—polycystic ovary syndrome	0.00144	0.00396	CbGeAlD
Nilotinib—TEK—adrenal gland—polycystic ovary syndrome	0.00142	0.00392	CbGeAlD
Nilotinib—CSF1R—endometrium—polycystic ovary syndrome	0.00141	0.00387	CbGeAlD
Nilotinib—CA9—endocrine gland—polycystic ovary syndrome	0.0014	0.00384	CbGeAlD
Nilotinib—PDGFRB—adrenal cortex—polycystic ovary syndrome	0.0014	0.00384	CbGeAlD
Nilotinib—EPHB4—female gonad—polycystic ovary syndrome	0.00139	0.00382	CbGeAlD
Nilotinib—Eye disorder—Metformin—polycystic ovary syndrome	0.00138	0.0127	CcSEcCtD
Nilotinib—EPHB4—vagina—polycystic ovary syndrome	0.00138	0.0038	CbGeAlD
Nilotinib—Flushing—Metformin—polycystic ovary syndrome	0.00137	0.0126	CcSEcCtD
Nilotinib—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00137	0.0126	CcSEcCtD
Nilotinib—MAPK14—endocrine gland—polycystic ovary syndrome	0.00136	0.00375	CbGeAlD
Nilotinib—EPHA2—female gonad—polycystic ovary syndrome	0.00136	0.00375	CbGeAlD
Nilotinib—EPHB6—adrenal gland—polycystic ovary syndrome	0.00136	0.00375	CbGeAlD
Nilotinib—FGR—endocrine gland—polycystic ovary syndrome	0.00136	0.00373	CbGeAlD
Nilotinib—EPHA2—vagina—polycystic ovary syndrome	0.00135	0.00372	CbGeAlD
Nilotinib—Angiopathy—Metformin—polycystic ovary syndrome	0.00134	0.0123	CcSEcCtD
Nilotinib—Immune system disorder—Metformin—polycystic ovary syndrome	0.00134	0.0122	CcSEcCtD
Nilotinib—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.00133	0.0122	CcSEcCtD
Nilotinib—TEK—female gonad—polycystic ovary syndrome	0.00133	0.00365	CbGeAlD
Nilotinib—Chills—Metformin—polycystic ovary syndrome	0.00133	0.0122	CcSEcCtD
Nilotinib—MAP2K5—pituitary gland—polycystic ovary syndrome	0.0013	0.00359	CbGeAlD
Nilotinib—MAP2K5—adipose tissue—polycystic ovary syndrome	0.0013	0.00357	CbGeAlD
Nilotinib—CSF1R—uterus—polycystic ovary syndrome	0.00129	0.00356	CbGeAlD
Nilotinib—EPHB4—endocrine gland—polycystic ovary syndrome	0.00129	0.00355	CbGeAlD
Nilotinib—PDGFRA—adrenal gland—polycystic ovary syndrome	0.00129	0.00355	CbGeAlD
Nilotinib—Erythema—Metformin—polycystic ovary syndrome	0.00129	0.0118	CcSEcCtD
Nilotinib—Malnutrition—Metformin—polycystic ovary syndrome	0.00129	0.0118	CcSEcCtD
Nilotinib—KIT—endometrium—polycystic ovary syndrome	0.00128	0.00351	CbGeAlD
Nilotinib—CSF1R—pituitary gland—polycystic ovary syndrome	0.00127	0.0035	CbGeAlD
Nilotinib—EPHB6—female gonad—polycystic ovary syndrome	0.00127	0.00349	CbGeAlD
Nilotinib—Flatulence—Metformin—polycystic ovary syndrome	0.00127	0.0116	CcSEcCtD
Nilotinib—CSF1R—adipose tissue—polycystic ovary syndrome	0.00127	0.00349	CbGeAlD
Nilotinib—EPHA2—endocrine gland—polycystic ovary syndrome	0.00127	0.00348	CbGeAlD
Nilotinib—EPHB6—vagina—polycystic ovary syndrome	0.00126	0.00347	CbGeAlD
Nilotinib—Dysgeusia—Metformin—polycystic ovary syndrome	0.00126	0.0116	CcSEcCtD
Nilotinib—PDGFRB—endometrium—polycystic ovary syndrome	0.00125	0.00343	CbGeAlD
Nilotinib—ABL1—adrenal cortex—polycystic ovary syndrome	0.00124	0.00342	CbGeAlD
Nilotinib—Muscle spasms—Metformin—polycystic ovary syndrome	0.00124	0.0113	CcSEcCtD
Nilotinib—TEK—endocrine gland—polycystic ovary syndrome	0.00124	0.0034	CbGeAlD
Nilotinib—Vision blurred—Metformin—polycystic ovary syndrome	0.00121	0.0111	CcSEcCtD
Nilotinib—Tremor—Metformin—polycystic ovary syndrome	0.00121	0.0111	CcSEcCtD
Nilotinib—PDGFRA—female gonad—polycystic ovary syndrome	0.0012	0.00331	CbGeAlD
Nilotinib—PDGFRA—vagina—polycystic ovary syndrome	0.0012	0.00329	CbGeAlD
Nilotinib—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.00119	0.0109	CcSEcCtD
Nilotinib—KIT—uterus—polycystic ovary syndrome	0.00118	0.00324	CbGeAlD
Nilotinib—MAP2K5—adrenal gland—polycystic ovary syndrome	0.00116	0.0032	CbGeAlD
Nilotinib—Malaise—Metformin—polycystic ovary syndrome	0.00116	0.0106	CcSEcCtD
Nilotinib—KIT—pituitary gland—polycystic ovary syndrome	0.00115	0.00318	CbGeAlD
Nilotinib—Syncope—Metformin—polycystic ovary syndrome	0.00115	0.0106	CcSEcCtD
Nilotinib—KIT—adipose tissue—polycystic ovary syndrome	0.00115	0.00317	CbGeAlD
Nilotinib—PDGFRB—uterus—polycystic ovary syndrome	0.00115	0.00316	CbGeAlD
Nilotinib—Palpitations—Metformin—polycystic ovary syndrome	0.00114	0.0104	CcSEcCtD
Nilotinib—CSF1R—adrenal gland—polycystic ovary syndrome	0.00114	0.00313	CbGeAlD
Nilotinib—Loss of consciousness—Metformin—polycystic ovary syndrome	0.00113	0.0104	CcSEcCtD
Nilotinib—PDGFRB—pituitary gland—polycystic ovary syndrome	0.00113	0.0031	CbGeAlD
Nilotinib—PDGFRB—adipose tissue—polycystic ovary syndrome	0.00112	0.00309	CbGeAlD
Nilotinib—PDGFRA—endocrine gland—polycystic ovary syndrome	0.00112	0.00308	CbGeAlD
Nilotinib—Hypertension—Metformin—polycystic ovary syndrome	0.00111	0.0102	CcSEcCtD
Nilotinib—ABL1—endometrium—polycystic ovary syndrome	0.00111	0.00306	CbGeAlD
Nilotinib—Chest pain—Metformin—polycystic ovary syndrome	0.0011	0.01	CcSEcCtD
Nilotinib—Myalgia—Metformin—polycystic ovary syndrome	0.0011	0.01	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00109	0.00998	CcSEcCtD
Nilotinib—MAP2K5—female gonad—polycystic ovary syndrome	0.00109	0.00299	CbGeAlD
Nilotinib—Discomfort—Metformin—polycystic ovary syndrome	0.00108	0.00992	CcSEcCtD
Nilotinib—MAP2K5—vagina—polycystic ovary syndrome	0.00108	0.00297	CbGeAlD
Nilotinib—UGT1A1—endocrine gland—polycystic ovary syndrome	0.00107	0.00294	CbGeAlD
Nilotinib—CSF1R—female gonad—polycystic ovary syndrome	0.00106	0.00292	CbGeAlD
Nilotinib—CSF1R—vagina—polycystic ovary syndrome	0.00105	0.0029	CbGeAlD
Nilotinib—CA1—adipose tissue—polycystic ovary syndrome	0.00105	0.00289	CbGeAlD
Nilotinib—Oedema—Metformin—polycystic ovary syndrome	0.00105	0.00963	CcSEcCtD
Nilotinib—Infection—Metformin—polycystic ovary syndrome	0.00104	0.00957	CcSEcCtD
Nilotinib—CA2—embryo—polycystic ovary syndrome	0.00103	0.00284	CbGeAlD
Nilotinib—Shock—Metformin—polycystic ovary syndrome	0.00103	0.00947	CcSEcCtD
Nilotinib—CA12—endocrine gland—polycystic ovary syndrome	0.00103	0.00284	CbGeAlD
Nilotinib—KIT—adrenal gland—polycystic ovary syndrome	0.00103	0.00284	CbGeAlD
Nilotinib—Nervous system disorder—Metformin—polycystic ovary syndrome	0.00103	0.00944	CcSEcCtD
Nilotinib—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.00103	0.00943	CcSEcCtD
Nilotinib—ABL1—uterus—polycystic ovary syndrome	0.00102	0.00282	CbGeAlD
Nilotinib—Skin disorder—Metformin—polycystic ovary syndrome	0.00102	0.00935	CcSEcCtD
Nilotinib—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.00102	0.00931	CcSEcCtD
Nilotinib—MAP2K5—endocrine gland—polycystic ovary syndrome	0.00101	0.00278	CbGeAlD
Nilotinib—PDGFRB—adrenal gland—polycystic ovary syndrome	0.00101	0.00277	CbGeAlD
Nilotinib—ABL1—pituitary gland—polycystic ovary syndrome	0.00101	0.00277	CbGeAlD
Nilotinib—Anorexia—Metformin—polycystic ovary syndrome	0.001	0.00918	CcSEcCtD
Nilotinib—ABL1—adipose tissue—polycystic ovary syndrome	0.001	0.00276	CbGeAlD
Nilotinib—CSF1R—endocrine gland—polycystic ovary syndrome	0.000985	0.00271	CbGeAlD
Nilotinib—Hypotension—Metformin—polycystic ovary syndrome	0.000982	0.009	CcSEcCtD
Nilotinib—KIT—female gonad—polycystic ovary syndrome	0.000962	0.00265	CbGeAlD
Nilotinib—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000957	0.00877	CcSEcCtD
Nilotinib—KIT—vagina—polycystic ovary syndrome	0.000956	0.00263	CbGeAlD
Nilotinib—Paraesthesia—Metformin—polycystic ovary syndrome	0.000943	0.00865	CcSEcCtD
Nilotinib—PDGFRB—female gonad—polycystic ovary syndrome	0.000939	0.00259	CbGeAlD
Nilotinib—Dyspnoea—Metformin—polycystic ovary syndrome	0.000936	0.00858	CcSEcCtD
Nilotinib—PDGFRB—vagina—polycystic ovary syndrome	0.000934	0.00257	CbGeAlD
Nilotinib—Dyspepsia—Metformin—polycystic ovary syndrome	0.000925	0.00848	CcSEcCtD
Nilotinib—Decreased appetite—Metformin—polycystic ovary syndrome	0.000913	0.00837	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000907	0.00831	CcSEcCtD
Nilotinib—Fatigue—Metformin—polycystic ovary syndrome	0.000906	0.0083	CcSEcCtD
Nilotinib—Constipation—Metformin—polycystic ovary syndrome	0.000898	0.00823	CcSEcCtD
Nilotinib—ABL1—adrenal gland—polycystic ovary syndrome	0.000898	0.00247	CbGeAlD
Nilotinib—KIT—endocrine gland—polycystic ovary syndrome	0.000895	0.00246	CbGeAlD
Nilotinib—PDGFRB—endocrine gland—polycystic ovary syndrome	0.000874	0.0024	CbGeAlD
Nilotinib—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000866	0.00794	CcSEcCtD
Nilotinib—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000859	0.00787	CcSEcCtD
Nilotinib—CA2—adrenal cortex—polycystic ovary syndrome	0.000847	0.00233	CbGeAlD
Nilotinib—ABL1—female gonad—polycystic ovary syndrome	0.000837	0.0023	CbGeAlD
Nilotinib—Urticaria—Metformin—polycystic ovary syndrome	0.000834	0.00765	CcSEcCtD
Nilotinib—ABL1—vagina—polycystic ovary syndrome	0.000832	0.00229	CbGeAlD
Nilotinib—Abdominal pain—Metformin—polycystic ovary syndrome	0.00083	0.00761	CcSEcCtD
Nilotinib—CA4—pituitary gland—polycystic ovary syndrome	0.000825	0.00227	CbGeAlD
Nilotinib—CA4—adipose tissue—polycystic ovary syndrome	0.000822	0.00226	CbGeAlD
Nilotinib—CA1—endocrine gland—polycystic ovary syndrome	0.000818	0.00225	CbGeAlD
Nilotinib—ABCG2—adrenal cortex—polycystic ovary syndrome	0.000784	0.00216	CbGeAlD
Nilotinib—ABL1—endocrine gland—polycystic ovary syndrome	0.000779	0.00214	CbGeAlD
Nilotinib—Asthenia—Metformin—polycystic ovary syndrome	0.000754	0.00691	CcSEcCtD
Nilotinib—Pruritus—Metformin—polycystic ovary syndrome	0.000743	0.00681	CcSEcCtD
Nilotinib—CA4—adrenal gland—polycystic ovary syndrome	0.000737	0.00203	CbGeAlD
Nilotinib—CYP2B6—adrenal cortex—polycystic ovary syndrome	0.000724	0.00199	CbGeAlD
Nilotinib—CYP2C8—endometrium—polycystic ovary syndrome	0.00072	0.00198	CbGeAlD
Nilotinib—Diarrhoea—Metformin—polycystic ovary syndrome	0.000719	0.00659	CcSEcCtD
Nilotinib—ABCG2—endometrium—polycystic ovary syndrome	0.000701	0.00193	CbGeAlD
Nilotinib—Dizziness—Metformin—polycystic ovary syndrome	0.000695	0.00637	CcSEcCtD
Nilotinib—CA4—female gonad—polycystic ovary syndrome	0.000688	0.00189	CbGeAlD
Nilotinib—CA2—pituitary gland—polycystic ovary syndrome	0.000684	0.00188	CbGeAlD
Nilotinib—CA2—adipose tissue—polycystic ovary syndrome	0.000682	0.00188	CbGeAlD
Nilotinib—Vomiting—Metformin—polycystic ovary syndrome	0.000668	0.00612	CcSEcCtD
Nilotinib—Rash—Metformin—polycystic ovary syndrome	0.000662	0.00607	CcSEcCtD
Nilotinib—Dermatitis—Metformin—polycystic ovary syndrome	0.000662	0.00607	CcSEcCtD
Nilotinib—Headache—Metformin—polycystic ovary syndrome	0.000658	0.00603	CcSEcCtD
Nilotinib—CYP2C8—pituitary gland—polycystic ovary syndrome	0.000652	0.00179	CbGeAlD
Nilotinib—ABCG2—uterus—polycystic ovary syndrome	0.000646	0.00178	CbGeAlD
Nilotinib—CA4—endocrine gland—polycystic ovary syndrome	0.000639	0.00176	CbGeAlD
Nilotinib—ABCG2—pituitary gland—polycystic ovary syndrome	0.000634	0.00174	CbGeAlD
Nilotinib—ABCG2—adipose tissue—polycystic ovary syndrome	0.000631	0.00174	CbGeAlD
Nilotinib—Nausea—Metformin—polycystic ovary syndrome	0.000624	0.00572	CcSEcCtD
Nilotinib—CA2—adrenal gland—polycystic ovary syndrome	0.000611	0.00168	CbGeAlD
Nilotinib—CA2—female gonad—polycystic ovary syndrome	0.00057	0.00157	CbGeAlD
Nilotinib—CA2—vagina—polycystic ovary syndrome	0.000567	0.00156	CbGeAlD
Nilotinib—ABCG2—adrenal gland—polycystic ovary syndrome	0.000566	0.00156	CbGeAlD
Nilotinib—CYP2C8—vagina—polycystic ovary syndrome	0.00054	0.00149	CbGeAlD
Nilotinib—CA2—endocrine gland—polycystic ovary syndrome	0.00053	0.00146	CbGeAlD
Nilotinib—ABCG2—female gonad—polycystic ovary syndrome	0.000528	0.00145	CbGeAlD
Nilotinib—ABCG2—vagina—polycystic ovary syndrome	0.000525	0.00144	CbGeAlD
Nilotinib—CYP2B6—adrenal gland—polycystic ovary syndrome	0.000522	0.00144	CbGeAlD
Nilotinib—CYP2C8—endocrine gland—polycystic ovary syndrome	0.000505	0.00139	CbGeAlD
Nilotinib—CYP2B6—vagina—polycystic ovary syndrome	0.000484	0.00133	CbGeAlD
Nilotinib—ABCB1—embryo—polycystic ovary syndrome	0.000472	0.0013	CbGeAlD
Nilotinib—CYP2B6—endocrine gland—polycystic ovary syndrome	0.000453	0.00125	CbGeAlD
Nilotinib—CYP2C9—endocrine gland—polycystic ovary syndrome	0.000449	0.00123	CbGeAlD
Nilotinib—ABCB1—adrenal cortex—polycystic ovary syndrome	0.000387	0.00106	CbGeAlD
Nilotinib—CYP2D6—female gonad—polycystic ovary syndrome	0.000362	0.000996	CbGeAlD
Nilotinib—ABCB1—endometrium—polycystic ovary syndrome	0.000345	0.000951	CbGeAlD
Nilotinib—CYP3A4—endocrine gland—polycystic ovary syndrome	0.000342	0.000941	CbGeAlD
Nilotinib—CYP2D6—endocrine gland—polycystic ovary syndrome	0.000337	0.000926	CbGeAlD
Nilotinib—ABCB1—uterus—polycystic ovary syndrome	0.000318	0.000876	CbGeAlD
Nilotinib—ABCB1—pituitary gland—polycystic ovary syndrome	0.000313	0.00086	CbGeAlD
Nilotinib—ABCB1—adipose tissue—polycystic ovary syndrome	0.000311	0.000857	CbGeAlD
Nilotinib—ABCB1—adrenal gland—polycystic ovary syndrome	0.000279	0.000769	CbGeAlD
Nilotinib—ABCB1—female gonad—polycystic ovary syndrome	0.00026	0.000717	CbGeAlD
Nilotinib—ABCB1—vagina—polycystic ovary syndrome	0.000259	0.000712	CbGeAlD
Nilotinib—ABCB1—endocrine gland—polycystic ovary syndrome	0.000242	0.000666	CbGeAlD
Nilotinib—CYP2C8—Metabolism—YAP1—polycystic ovary syndrome	1.12e-05	2.12e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—AKT2—polycystic ovary syndrome	1.12e-05	2.12e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—MTHFR—polycystic ovary syndrome	1.12e-05	2.12e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NGFR—polycystic ovary syndrome	1.11e-05	2.11e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—LEP—polycystic ovary syndrome	1.11e-05	2.11e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—IRS2—polycystic ovary syndrome	1.11e-05	2.11e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NRG1—polycystic ovary syndrome	1.11e-05	2.1e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—HSD3B2—polycystic ovary syndrome	1.11e-05	2.1e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PRL—polycystic ovary syndrome	1.1e-05	2.09e-05	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—IL6—polycystic ovary syndrome	1.1e-05	2.09e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IRS1—polycystic ovary syndrome	1.1e-05	2.09e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—HSD3B2—polycystic ovary syndrome	1.1e-05	2.08e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IRS1—polycystic ovary syndrome	1.09e-05	2.07e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—NAMPT—polycystic ovary syndrome	1.08e-05	2.04e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IRS2—polycystic ovary syndrome	1.08e-05	2.04e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—NCOR1—polycystic ovary syndrome	1.07e-05	2.03e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	1.07e-05	2.03e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.07e-05	2.03e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.07e-05	2.03e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CYP11A1—polycystic ovary syndrome	1.06e-05	2.02e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—SERPINE1—polycystic ovary syndrome	1.06e-05	2.01e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—SERPINE1—polycystic ovary syndrome	1.06e-05	2.01e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AKR1C1—polycystic ovary syndrome	1.06e-05	2.01e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—POMC—polycystic ovary syndrome	1.06e-05	2.01e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—BCL2—polycystic ovary syndrome	1.06e-05	2.01e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.06e-05	2e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	1.05e-05	2e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—INS—polycystic ovary syndrome	1.05e-05	2e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—LEP—polycystic ovary syndrome	1.05e-05	2e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IRS1—polycystic ovary syndrome	1.05e-05	1.99e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NRG1—polycystic ovary syndrome	1.05e-05	1.99e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—POMC—polycystic ovary syndrome	1.05e-05	1.99e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.05e-05	1.99e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—SULT2A1—polycystic ovary syndrome	1.05e-05	1.98e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—INS—polycystic ovary syndrome	1.04e-05	1.98e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—IL6—polycystic ovary syndrome	1.04e-05	1.98e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—IL6—polycystic ovary syndrome	1.04e-05	1.98e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—IL6—polycystic ovary syndrome	1.04e-05	1.97e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—BCL2—polycystic ovary syndrome	1.04e-05	1.96e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—BCL2—polycystic ovary syndrome	1.03e-05	1.95e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IGF1—polycystic ovary syndrome	1.02e-05	1.93e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AKT2—polycystic ovary syndrome	1.02e-05	1.93e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—CYP1A1—polycystic ovary syndrome	1.02e-05	1.93e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—RRM2—polycystic ovary syndrome	1.01e-05	1.92e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—TH—polycystic ovary syndrome	1.01e-05	1.92e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IGF1—polycystic ovary syndrome	1.01e-05	1.91e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AKT2—polycystic ovary syndrome	1.01e-05	1.91e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AKR1C3—polycystic ovary syndrome	1e-05	1.9e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	1e-05	1.9e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IRS1—polycystic ovary syndrome	9.92e-06	1.88e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CYP17A1—polycystic ovary syndrome	9.89e-06	1.87e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—IL6—polycystic ovary syndrome	9.88e-06	1.87e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—IL6—polycystic ovary syndrome	9.87e-06	1.87e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	9.86e-06	1.87e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—SLC2A4—polycystic ovary syndrome	9.83e-06	1.86e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—BCL2—polycystic ovary syndrome	9.82e-06	1.86e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—SULT2A1—polycystic ovary syndrome	9.77e-06	1.85e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—YAP1—polycystic ovary syndrome	9.76e-06	1.85e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—AKT2—polycystic ovary syndrome	9.72e-06	1.84e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—GNAS—polycystic ovary syndrome	9.71e-06	1.84e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—IRS1—polycystic ovary syndrome	9.7e-06	1.84e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IRS2—polycystic ovary syndrome	9.69e-06	1.84e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—SERPINE1—polycystic ovary syndrome	9.68e-06	1.83e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—SERPINE1—polycystic ovary syndrome	9.59e-06	1.82e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—POMC—polycystic ovary syndrome	9.56e-06	1.81e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	9.54e-06	1.81e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	9.54e-06	1.81e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—INS—polycystic ovary syndrome	9.5e-06	1.8e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IRS2—polycystic ovary syndrome	9.49e-06	1.8e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—LEP—polycystic ovary syndrome	9.49e-06	1.8e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—MTHFR—polycystic ovary syndrome	9.47e-06	1.8e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—RRM2—polycystic ovary syndrome	9.46e-06	1.79e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—IL6—polycystic ovary syndrome	9.4e-06	1.78e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IRS1—polycystic ovary syndrome	9.39e-06	1.78e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	9.38e-06	1.78e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—LEP—polycystic ovary syndrome	9.29e-06	1.76e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—INS—polycystic ovary syndrome	9.29e-06	1.76e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	9.26e-06	1.76e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NCOR1—polycystic ovary syndrome	9.25e-06	1.75e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CYP19A1—polycystic ovary syndrome	9.24e-06	1.75e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—IL6—polycystic ovary syndrome	9.21e-06	1.75e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	9.2e-06	1.74e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IGF1—polycystic ovary syndrome	9.19e-06	1.74e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AKT2—polycystic ovary syndrome	9.18e-06	1.74e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—IL6—polycystic ovary syndrome	9.16e-06	1.74e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—YAP1—polycystic ovary syndrome	9.12e-06	1.73e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—IL6—polycystic ovary syndrome	9.11e-06	1.73e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NRG1—polycystic ovary syndrome	9.08e-06	1.72e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PPARG—polycystic ovary syndrome	9.05e-06	1.72e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—POMC—polycystic ovary syndrome	9.04e-06	1.71e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IRS2—polycystic ovary syndrome	9e-06	1.71e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—INS—polycystic ovary syndrome	8.99e-06	1.7e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—AKT2—polycystic ovary syndrome	8.98e-06	1.7e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL6—polycystic ovary syndrome	8.94e-06	1.69e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL6—polycystic ovary syndrome	8.94e-06	1.69e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—POMC—polycystic ovary syndrome	8.93e-06	1.69e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL6—polycystic ovary syndrome	8.91e-06	1.69e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—INS—polycystic ovary syndrome	8.88e-06	1.68e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	8.84e-06	1.68e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—LEP—polycystic ovary syndrome	8.8e-06	1.67e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—NAMPT—polycystic ovary syndrome	8.76e-06	1.66e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	8.75e-06	1.66e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	8.73e-06	1.65e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—SERPINE1—polycystic ovary syndrome	8.73e-06	1.65e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—IL6—polycystic ovary syndrome	8.73e-06	1.65e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	8.71e-06	1.65e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IGF1—polycystic ovary syndrome	8.7e-06	1.65e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AKT2—polycystic ovary syndrome	8.69e-06	1.65e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CYP11A1—polycystic ovary syndrome	8.65e-06	1.64e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	8.61e-06	1.63e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	8.59e-06	1.63e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—TH—polycystic ovary syndrome	8.55e-06	1.62e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—SERPINE1—polycystic ovary syndrome	8.53e-06	1.62e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	8.5e-06	1.61e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—BCL2—polycystic ovary syndrome	8.49e-06	1.61e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IRS1—polycystic ovary syndrome	8.46e-06	1.6e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—VEGFA—polycystic ovary syndrome	8.36e-06	1.58e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—SLC2A4—polycystic ovary syndrome	8.32e-06	1.58e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IRS1—polycystic ovary syndrome	8.28e-06	1.57e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—SERPINE1—polycystic ovary syndrome	8.26e-06	1.57e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—GNAS—polycystic ovary syndrome	8.25e-06	1.56e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	8.24e-06	1.56e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AKR1C3—polycystic ovary syndrome	8.17e-06	1.55e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—POMC—polycystic ovary syndrome	8.15e-06	1.54e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	8.12e-06	1.54e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	8.11e-06	1.54e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—INS—polycystic ovary syndrome	8.1e-06	1.54e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CYP17A1—polycystic ovary syndrome	8.05e-06	1.53e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—POMC—polycystic ovary syndrome	7.98e-06	1.51e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—VEGFA—polycystic ovary syndrome	7.94e-06	1.51e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—INS—polycystic ovary syndrome	7.93e-06	1.5e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—NCOR1—polycystic ovary syndrome	7.86e-06	1.49e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IRS1—polycystic ovary syndrome	7.85e-06	1.49e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IGF1—polycystic ovary syndrome	7.84e-06	1.49e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AKT2—polycystic ovary syndrome	7.83e-06	1.48e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CYP19A1—polycystic ovary syndrome	7.82e-06	1.48e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IRS2—polycystic ovary syndrome	7.78e-06	1.47e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PPARG—polycystic ovary syndrome	7.68e-06	1.46e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IGF1—polycystic ovary syndrome	7.67e-06	1.45e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AKT2—polycystic ovary syndrome	7.67e-06	1.45e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—LEP—polycystic ovary syndrome	7.61e-06	1.44e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—POMC—polycystic ovary syndrome	7.58e-06	1.44e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—POMC—polycystic ovary syndrome	7.56e-06	1.43e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—IL6—polycystic ovary syndrome	7.55e-06	1.43e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—INS—polycystic ovary syndrome	7.53e-06	1.43e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—INS—polycystic ovary syndrome	7.52e-06	1.43e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—TH—polycystic ovary syndrome	7.45e-06	1.41e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CYP1A1—polycystic ovary syndrome	7.45e-06	1.41e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—SERPINE1—polycystic ovary syndrome	7.44e-06	1.41e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	7.4e-06	1.4e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SERPINE1—polycystic ovary syndrome	7.29e-06	1.38e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IGF1—polycystic ovary syndrome	7.27e-06	1.38e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AKT2—polycystic ovary syndrome	7.27e-06	1.38e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	7.25e-06	1.37e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	7.23e-06	1.37e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL6—polycystic ovary syndrome	7.12e-06	1.35e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—TH—polycystic ovary syndrome	7.02e-06	1.33e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	7e-06	1.33e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GNAS—polycystic ovary syndrome	6.98e-06	1.32e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—TH—polycystic ovary syndrome	6.96e-06	1.32e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—MTHFR—polycystic ovary syndrome	6.94e-06	1.32e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SERPINE1—polycystic ovary syndrome	6.91e-06	1.31e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	6.83e-06	1.29e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	6.82e-06	1.29e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IRS1—polycystic ovary syndrome	6.79e-06	1.29e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—SLC2A4—polycystic ovary syndrome	6.77e-06	1.28e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.66e-06	1.26e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—NCOR1—polycystic ovary syndrome	6.65e-06	1.26e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.6e-06	1.25e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—POMC—polycystic ovary syndrome	6.54e-06	1.24e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—IL6—polycystic ovary syndrome	6.51e-06	1.23e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—INS—polycystic ovary syndrome	6.5e-06	1.23e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	6.44e-06	1.22e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	6.42e-06	1.22e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL6—polycystic ovary syndrome	6.42e-06	1.22e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CYP19A1—polycystic ovary syndrome	6.37e-06	1.21e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CYP1A1—polycystic ovary syndrome	6.31e-06	1.2e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IGF1—polycystic ovary syndrome	6.29e-06	1.19e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AKT2—polycystic ovary syndrome	6.29e-06	1.19e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	6.24e-06	1.18e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	6.08e-06	1.15e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL6—polycystic ovary syndrome	6.08e-06	1.15e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	6.02e-06	1.14e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—VEGFA—polycystic ovary syndrome	6e-06	1.14e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.97e-06	1.13e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—IL6—polycystic ovary syndrome	5.93e-06	1.12e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—MTHFR—polycystic ovary syndrome	5.88e-06	1.11e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	5.8e-06	1.1e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL6—polycystic ovary syndrome	5.78e-06	1.1e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	5.78e-06	1.1e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	5.73e-06	1.09e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	5.71e-06	1.08e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GNAS—polycystic ovary syndrome	5.68e-06	1.08e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—VEGFA—polycystic ovary syndrome	5.68e-06	1.08e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PPARG—polycystic ovary syndrome	5.63e-06	1.07e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—IL6—polycystic ovary syndrome	5.61e-06	1.06e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—POMC—polycystic ovary syndrome	5.55e-06	1.05e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—INS—polycystic ovary syndrome	5.52e-06	1.05e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL6—polycystic ovary syndrome	5.49e-06	1.04e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	5.49e-06	1.04e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL6—polycystic ovary syndrome	5.48e-06	1.04e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	5.46e-06	1.04e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—NCOR1—polycystic ovary syndrome	5.41e-06	1.03e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	5.39e-06	1.02e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6—polycystic ovary syndrome	5.36e-06	1.02e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6—polycystic ovary syndrome	5.34e-06	1.01e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	5.31e-06	1.01e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	5.18e-06	9.81e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CYP1A1—polycystic ovary syndrome	5.13e-06	9.73e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	5.12e-06	9.71e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—polycystic ovary syndrome	5.12e-06	9.7e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6—polycystic ovary syndrome	5.08e-06	9.64e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6—polycystic ovary syndrome	5.06e-06	9.58e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—polycystic ovary syndrome	5.01e-06	9.5e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	4.83e-06	9.15e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—MTHFR—polycystic ovary syndrome	4.78e-06	9.07e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PPARG—polycystic ovary syndrome	4.77e-06	9.04e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.75e-06	9.01e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—POMC—polycystic ovary syndrome	4.7e-06	8.91e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—INS—polycystic ovary syndrome	4.68e-06	8.86e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6—polycystic ovary syndrome	4.6e-06	8.73e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TH—polycystic ovary syndrome	4.59e-06	8.7e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6—polycystic ovary syndrome	4.56e-06	8.65e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	4.47e-06	8.47e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6—polycystic ovary syndrome	4.4e-06	8.33e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	4.2e-06	7.96e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	4.15e-06	7.87e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6—polycystic ovary syndrome	4.15e-06	7.87e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.11e-06	7.79e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—POMC—polycystic ovary syndrome	4.1e-06	7.76e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—INS—polycystic ovary syndrome	4.07e-06	7.72e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6—polycystic ovary syndrome	4.06e-06	7.69e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6—polycystic ovary syndrome	3.93e-06	7.45e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	3.91e-06	7.42e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PPARG—polycystic ovary syndrome	3.88e-06	7.35e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	3.86e-06	7.32e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—INS—polycystic ovary syndrome	3.84e-06	7.28e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—POMC—polycystic ovary syndrome	3.83e-06	7.25e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—INS—polycystic ovary syndrome	3.81e-06	7.21e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	3.75e-06	7.1e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	3.57e-06	6.77e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6—polycystic ovary syndrome	3.54e-06	6.71e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6—polycystic ovary syndrome	3.47e-06	6.57e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	3.38e-06	6.42e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6—polycystic ovary syndrome	3.29e-06	6.23e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	3.16e-06	5.98e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6—polycystic ovary syndrome	2.84e-06	5.39e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	2.56e-06	4.85e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	2.52e-06	4.78e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—INS—polycystic ovary syndrome	2.51e-06	4.76e-06	CbGpPWpGaD
